Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.72 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.67 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.67 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.67 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.67 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.67 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.67 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.67 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.67 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.67 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.67 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.67 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.67 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.67 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.67 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.67 |
| ▸ | RARB | P10826 | 6/20 | 0.59 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 3/20 | 0.57 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13131603 | 0.94 | MAPT (0.66) | HSD17B10SMN1; SMN2HDAC3MAPK1ADRA1A | |
| SCHEMBL11569566 | 0.92 | MAPT (0.69) | HSD17B10SMN1; SMN2HDAC3MAPK1ADRA1A | |
| SCHEMBL12834782 | 0.92 | MAPT (0.69) | HSD17B10SMN1; SMN2HDAC3MAPK1ADRA1A | |
| SCHEMBL6208836 | 0.89 | SMN1; SMN2 (0.82) | HSD17B10SMN1; SMN2HDAC3MAPK1ADRA1A | |
| SCHEMBL264975 | 0.87 | FFAR1 (0.65) | HSD17B10RARBFFAR1ALDH1A1TSHR | |
| SCHEMBL371605 | 0.87 | RARB (0.71) | HSD17B10SMN1; SMN2HDAC1HDAC8RARB | |
| SCHEMBL133470 | 0.87 | RARB (0.68) | HSD17B10HDAC1HDAC8RARBMAPT | |
| SCHEMBL69789 | 0.87 | SMN1; SMN2 (0.78) | HSD17B10SMN1; SMN2HDAC3MAPK1ADRA1A | |
| SCHEMBL9472454 | 0.85 | RARB (0.72) | HSD17B10HDAC1RARBMAPTRXFP1 | |
| SCHEMBL30053056 | 0.85 | RARB (0.72) | HSD17B10HDAC1RARBMAPTRXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105785713-B | Photosensitive resin composition, dry film, cured product, member or product, and adhesive | 太阳控股株式会社 | 2022-06-03 | — | — | CN | disclosed |
| US-9688737-B2 | Protease stabilized acylated insulin analogues | NOVO NORDISK A/S (DK) | 2017-06-27 | — | — | US | disclosed |
| US-9512195-B2 | Insulin derivatives containing additional disulfide bonds | NOVO NORDISK A/S (DK) | 2016-12-06 | — | — | US | disclosed |
| US-20150210747-A1 | PROTEASE STABILIZED ACYLATED INSULIN ANALOGUES | NOVO NORDISK AS (DK) | 2015-07-30 | — | — | US | disclosed |
| US-9045560-B2 | Protease stabilized, acylated insulin analogues | NOVO NORDISK A/S (DK) | 2015-06-02 | — | — | US | disclosed |
| US-20140371140-A1 | Insulin derivatives Containing Additional Disulfide bonds | NOVO NORDISK AS (DK) | 2014-12-18 | — | — | US | disclosed |
| US-8680159-B2 | Bradykinin 1 receptor modulating compounds | GRUENENTHAL GMBH (DE) | 2014-03-25 | — | — | US | disclosed |
| US-8680159-B2 | Bradykinin 1 receptor modulating compounds | GRUENENTHAL GMBH (DE) | 2014-03-25 | — | — | US | disclosed |
| US-20140073564-A1 | PROTEASE STABILIZED, ACYLATED INSULIN ANALOGUES | NOVO NORDISK A/S (DK) | 2014-03-13 | — | — | US | disclosed |
| WO-2012038081-A1 | SUBSTITUTED BENZAMIDE COMPOUNDS | Grünenthal GmbH (DE) | 2012-03-29 | — | — | WO | disclosed |
| US-5635477-A | CYCLIC TETRAPEPTIDE DERIVATIVE FUSED TO A BENZENE RING; ANTICOAGULANTS; THROMBOLYTICS; CLOT LYSIS | THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) | 1997-06-03 | — | — | US | disclosed |
| EP-0699209-A1 | PROCESSES AND INTERMEDIATE COMPOUNDS USEFUL FOR THE PREPARATION OF PLATELET GLYCOPROTEIN IIb/IIIa INHIBITORS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1996-03-06 | — | — | EP | disclosed |
| EP-0692982-A1 | RADIOLABELED PLATELET GPIIb/IIIa RECEPTOR ANTAGONISTS AS IMAGING AGENTS FOR THE DIAGNOSIS OF THROMBOEMBOLIC DISORDERS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1996-01-24 | — | — | EP | disclosed |
| EP-0691987-A1 | CYCLIC COMPOUNDS USEFUL AS INHIBITORS OF PLATELET GLYCOPROTEIN IIb/IIIa | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1996-01-17 | — | — | EP | disclosed |
| WO-1995023811-A1 | NOVEL CARBOCYCLIC COMPOUNDS WHICH INHIBIT PLATELET AGGREGATION BY INTERACTION WITH THE GPIIB/IIIA RECEPTOR COMPLEX | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1995-09-08 | — | — | WO | disclosed |
| WO-1994026779-A1 | PROCESSES AND INTERMEDIATE COMPOUNDS USEFUL FOR THE PREPARATION OF PLATELET GLYCOPROTEIN IIb/IIIa INHIBITORS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1994-11-24 | — | — | WO | disclosed |
| EP-0625164-A1 | CYCLIC COMPOUNDS USEFUL AS INHIBITORS OF PLATELET GLYCOPROTEIN IIb/IIIa | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1994-11-23 | — | — | EP | disclosed |
| WO-1994022910-A1 | CYCLIC COMPOUNDS USEFUL AS INHIBITORS OF PLATELET GLYCOPROTEIN IIb/IIIa | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1994-10-13 | — | — | WO | disclosed |
| WO-1994022494-A1 | RADIOLABELED PLATELET GPIIb/IIIa RECEPTOR ANTAGONISTS AS IMAGING AGENTS FOR THE DIAGNOSIS OF THROMBOEMBOLIC DISORDERS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1994-10-13 | — | — | WO | disclosed |
| WO-1993007170-A1 | CYCLIC COMPOUNDS USEFUL AS INHIBITORS OF PLATELET GLYCOPROTEIN IIb/IIIa | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1993-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150210747-A1 | PROTEASE STABILIZED ACYLATED INSULIN ANALOGUES | IAPP, IDE, LIPE | HSD17B10 405/4885SMN1; SMN2 1218/4885HDAC3 302/4885 |
| US-20140073564-A1 | PROTEASE STABILIZED, ACYLATED INSULIN ANALOGUES | IAPP, IDE, LIPE | HSD17B10 455/4885SMN1; SMN2 1083/4885HDAC3 381/4885 |
| US-20140371140-A1 | Insulin derivatives Containing Additional Disulfide bonds | IAPP, IGFBP4, INSR | HSD17B10 129/4885SMN1; SMN2 3459/4885HDAC3 2002/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.